NBRV Nabriva Therapeutics Plc

Nabriva Therapeutics AG is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics.

$0.18
As of 07/01/2022     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Ireland
Country of incorporation:  Ireland
IPO date:  09/18/2015
Outstanding shares:  63,204,829
Average volume:  835,864
Market cap:   $12,956,990
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BYQMW23

---

Valuation   (See tab for details)

---

PE ratio:   -0.24
PB ratio:   0.25
PS ratio:   0.39
Return on equity:   -105.97%
Net income %:   -141.35%